Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 1;2(8):e25219.
doi: 10.4161/onci.25219. Epub 2013 Jun 10.

HDAC inhibitors and their potential applications to glioblastoma therapy

Eleni Adamopoulou  1 , Ulrike Naumann
Affiliations

HDAC inhibitors and their potential applications to glioblastoma therapy

Eleni Adamopoulou et al. Oncoimmunology. .

Abstract

Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytotoxic responses against glioblastoma cells that efficiently inhibit tumor growth.

Keywords: HDAC inhibition; NK cells; glioblastoma; immunomodulation.

PubMed Disclaimer

Figures

None
Figure 1. Antitumor activity of HDAC inhibitors. Left: The inhibition of histone deacetylases (HDACs) causes both transcriptional and non-transcriptional effects, leading to profound alterations in cell homeostasis. Middle: The re-acetylation of histones upon HDAC inhibition stimulates gene transcription. Right: As a result of HDAC inhibition, NKG2D ligands (NKG2DLs) such as MHC Class I-related chain A and B (MICA/B) or UL16-binding proteins (ULBPs) are upregulated, rendering glioblastoma multiforme (GBM) susceptible to recognition and lysis by natural killer (NK) cells.
See this image and copyright information in PMC

References

    1. Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 2006;129:2416–25. doi: 10.1093/brain/awl205. - DOI - PubMed
    1. Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 2003;63:8996–9006. - PubMed
    1. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol. 2011;206:13–37. doi: 10.1007/978-3-642-21631-2_2. - DOI - PubMed
    1. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1:19–25. doi: 10.1016/j.molonc.2007.01.001. - DOI - PMC - PubMed
    1. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;65:6321–9. doi: 10.1158/0008-5472.CAN-04-4252. - DOI - PubMed